P583 Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study
| Autor: | Antonio Tursi, Francesco Luzza, A De Monti, Cristiano Pagnini, Marilisa Franceschi, Simona Piergallini, M E Serio, Marcello Picchio, Giovanni Maconi, C Cicerone, N. Della Valle, G De Angelis, G. Mocci, Federica Gaiani, Giuseppe Pranzo, Sara Gallina, A Cuomo, Walter Elisei, A. Cocco, Giacomo Forti, Rodolfo Sacco, Roberto Faggiani, Tiziana Larussa, L Fanigliulo, G Aragona, L Donnarumma, Leonardo Allegretta, Raffaele Colucci, Roberto Lorenzetti, S. Rodinò, I Luppino, Antonio Penna, M.G. Graziani, Antonio Ferronato, A Scarcelli, Costantino Zampaletta, P. Perazzo, Ladislava Sebkova, Roberta Pica, Giuseppina Grasso |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Leukocyte L1 Antigen Complex Crohn's disease biology business.industry C-reactive protein Gastroenterology Mucous membrane General Medicine medicine.disease Vedolizumab medicine.anatomical_structure Internal medicine Ustekinumab biology.protein medicine Adverse effect business Cohort study medicine.drug |
| Zdroj: | Journal of Crohn's and Colitis. 15:S536-S537 |
| ISSN: | 1876-4479 1873-9946 |
| Popis: | Background Ustekinumab (UST) is an anti-IL12/23 antibody for the treatment of Crohn’s Disease (CD). The aim of this study was to compare the efficacy and safety of UST in a large population-based cohort of CD patients who failed previous treatment with other biologics Methods 194 CD patients (108 males and 86 females, mean age 48 years (range 38–58 years) were retrospectively reviewed. 147 patients were already treated with anti-TNFα (75.8%), and 47 (24.2%) patients were already treated with anti-TNFα and vedolizumab. Concomitant treatment with steroids was present in 177 (91.2%) patients Results At week 12, clinical remission was achieved in 146 (75.2%) patients. After a mean follow-up of 6 months, clinical remission was maintained in 135 (69.6%) patients; at that time, mucosal healing was assessed in 62 (31.9%) patients, and it was achieved in 33 (53.2) patients. Three (1.5%) patients were submitted to surgery. Steroid-free remission was achieved in 115 (59.3%) patients. Both serum C-Reactive Protein and Fecal Calprotectin (FC) levels were significantly reduced with respect to baseline levels during follow-up. A logistic regression, UST therapy as thirdline therapy (after both anti-TNFα and vedolizumab), FC >200 μg/g, and HBI ≥8 were significantly associated with lack of remission. Adverse events occurred in 5 (2.6%) patients, and four of them required suspension of treatment Conclusion Ustekinumab seemed to be really effective and safe in CD patients unresponsive to other biologic treatments, especially when used as second-line treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|